Longeveron (LGVN) Competitors $1.32 +0.02 (+1.15%) Closing price 07/3/2025 01:00 PM EasternExtended Trading$1.31 -0.01 (-0.68%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN vs. VNRX, SRZN, EPIX, PLRX, MGNX, ZURA, ONCY, QNCX, PYXS, and BMEAShould you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include VolitionRx (VNRX), Surrozen (SRZN), ESSA Pharma (EPIX), Pliant Therapeutics (PLRX), MacroGenics (MGNX), Zura Bio (ZURA), Oncolytics Biotech (ONCY), Quince Therapeutics (QNCX), Pyxis Oncology (PYXS), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. Longeveron vs. Its Competitors VolitionRx Surrozen ESSA Pharma Pliant Therapeutics MacroGenics Zura Bio Oncolytics Biotech Quince Therapeutics Pyxis Oncology Biomea Fusion VolitionRx (NYSE:VNRX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Do analysts recommend VNRX or LGVN? VolitionRx currently has a consensus price target of $3.50, suggesting a potential upside of 343.04%. Longeveron has a consensus price target of $8.67, suggesting a potential upside of 559.06%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than VolitionRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk and volatility, VNRX or LGVN? VolitionRx has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Does the media refer more to VNRX or LGVN? In the previous week, VolitionRx's average media sentiment score of 0.00 equaled Longeveron'saverage media sentiment score. Company Overall Sentiment VolitionRx Neutral Longeveron Neutral Is VNRX or LGVN more profitable? Longeveron has a net margin of -760.72% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Longeveron -760.72%-85.07%-70.74% Do insiders and institutionals hold more shares of VNRX or LGVN? 8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 10.4% of VolitionRx shares are owned by company insiders. Comparatively, 11.2% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, VNRX or LGVN? Longeveron has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.31M62.21-$35.32M-$0.27-2.93Longeveron$2.39M8.21-$15.97M-$6.28-0.21 SummaryLongeveron beats VolitionRx on 10 of the 14 factors compared between the two stocks. Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition Export to ExcelMetricLongeveronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.56M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.2121.5627.6120.24Price / Sales8.21278.93417.30118.22Price / CashN/A42.7336.8958.10Price / Book0.897.518.035.67Net Income-$15.97M-$55.14M$3.18B$249.21M7 Day Performance-0.38%4.61%2.93%3.28%1 Month Performance11.44%4.72%3.75%5.55%1 Year Performance-23.99%5.92%35.20%21.09% Longeveron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron3.3078 of 5 stars$1.32+1.2%$8.67+559.1%-20.3%$19.56M$2.39M-0.2120VNRXVolitionRx1.6967 of 5 stars$0.76-9.3%$3.50+360.5%+22.5%$78.30M$1.31M-2.1180SRZNSurrozen2.3836 of 5 stars$8.94-0.9%$38.50+330.6%-19.1%$77.24M$10.65M-0.3680Gap DownHigh Trading VolumeEPIXESSA Pharma1.2975 of 5 stars$1.70-1.7%$2.00+17.6%-63.7%$76.79MN/A-2.7050News CoveragePositive NewsPLRXPliant Therapeutics3.9903 of 5 stars$1.16-7.2%$13.31+1,047.6%-88.2%$76.73M$1.58M-0.3290High Trading VolumeMGNXMacroGenics4.1302 of 5 stars$1.21+1.7%$5.71+372.3%-65.7%$75.08M$149.96M-1.36430ZURAZura Bio3.3094 of 5 stars$1.05flat$14.33+1,265.1%-67.6%$71.79MN/A-1.503Positive NewsGap UpONCYOncolytics Biotech1.696 of 5 stars$0.77+3.0%$4.33+460.6%-10.8%$70.77MN/A-2.6730News CoverageQNCXQuince Therapeutics3.1466 of 5 stars$1.65+6.5%$8.00+384.8%+129.1%$70.48MN/A-1.1960PYXSPyxis Oncology1.2424 of 5 stars$1.10flat$9.00+718.2%-61.3%$68.14M$16.15M-0.6960News CoveragePositive NewsBMEABiomea Fusion2.5834 of 5 stars$1.80-0.6%$21.40+1,088.9%-62.0%$68.01MN/A-0.5150 Related Companies and Tools Related Companies VNRX Alternatives SRZN Alternatives EPIX Alternatives PLRX Alternatives MGNX Alternatives ZURA Alternatives ONCY Alternatives QNCX Alternatives PYXS Alternatives BMEA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGVN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
